Abstract. Hepatocyte growth factor (HGF) has been implicated in epithelial-mesenchymal transition (EMT) in numerous types of cancer. However, to the best of our knowledge, there has been no previous evidence that HGF has a role in prostate cancer. The present study aimed to investigate the effect of HGF on EMT and invasive potential, as well as the underlying molecular mechanisms, in a human prostate cancer cell line. Therefore, PC-3 cells were treated with various concentrations of HGF for varying durations. EMT-associated proteins, including E-cadherin and vimentin, were examined by western blot analysis. The effects of HGF on cell proliferation, migration, invasion and tumorigenicity were assessed using MTT, wound-healing, Transwell and soft-agar assays. Subsequently, the role of c-Met in the mediation of EMT-like changes was investigated using reverse transcription-polymerase chain reaction, western blot analysis and gene knockdown by small interfering RNA. Finally, western blot analysis was used to quantify the expression of a downstream transcription factor and extracellular signal-related kinase/mitogen activated protein kinase (ERK/MAPK) signaling pathway proteins. The results indicated that treatment with HGF induced EMT-like changes and enhanced the invasive potential of PC-3 cells. There was an increase in the expression of ERK, phosphorylated-ERK and zinc finger E-box binding homeobox-1 (Zeb-1), suggesting that EMT-like changes may be mediated through the ERK/MAPK and Zeb-1 signaling pathway. Furthermore, HGF-mediated EMT-like changes were associated with c-Met activation, and these changes were able to be blocked by c-Met knockdown. The present study demonstrated that HGF-induced EMT increased the invasive potential of PC-3 human prostate cancer cells through activating the ERK/MAPK and Zeb-1 signaling pathway.
Introduction
Worldwide, prostate cancer (PCa) is the second most commonly diagnosed type of cancer and sixth leadinwg cause of cancer-associated mortality among males (1) . Mortality associated with PCa results from distant metastasis, particularly to bone. Specifically, ~80% of patients with PCa succumb to bone metastasis, and up to 80% of patients with PCa exhibit bone metastasis at autopsy (2, 3) . However, the mechanisms underlying the metastasis of PCa remain to be elucidated.
In recent years, the epithelial-mesenchymal transition (EMT) has been established as a regulator of tumor aggressiveness (4) . EMT was originally identified during embryogenesis, where it was described as a crucial process involved in differentiation and morphogenesis (5) . EMT has additionally been attributed to tumor progression and metastasis (6) . During EMT, cancer cells lose epithelial characteristics and acquire mesenchymal properties, including fibroblastoid morphology, characteristic changes in gene expression and increased motility. Simultaneously, the cells develop characteristics of cancer stem cells (7) . These changes promote cancer cell invasiveness, metastasis and resistance to chemotherapy (8) (9) (10) .
Numerous factors induce EMT, including transforming growth factor-β (TGF-β), epidermal growth factor (EGF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), platelet-derived growth factor, insulin-like growth factor (IGF) (11) , hypoxia (11, 12) and micro RNA (13) . These factors induce EMT via various signaling pathways, including Wnt, Hedgehog and Notch (14, 15) .
In the present study, the association between HGF and EMT in prostate cancer was investigated. Previous studies have reported that higher plasma levels of HGF are associated with advanced stage and poor prognosis in patients with prostate cancer (16, 17) . This may be mediated by the promotion of EMT by HGF in cancer cells. However, the mechanisms by which HGF induces EMT remain unclear. The present study utilized the PC-3 human prostate cancer cell line as an experimental model. PC-3 cells are negative for EMT (18) (19) (20) (21) and positive for c-Met expression (22) . The present study investigated the effects of HGF on the EMT and invasive potential of PC-3 cells. Furthermore, the potential signaling pathways mediating this effect were investigated.
Materials and methods
Cell culture and treatment. PC-3 cells (American Type Culture Collection, Manassas, VA, USA) were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco Life Technologies, Carlsbad, CA, USA) supplemented with 10% (v/v) fetal bovine serum (FBS; Gibco Life Technologies) and incubated at 37˚C in an atmosphere containing 5% CO 2 . Cells were treated with recombinant human HGF (Sigma-Aldrich, St. Louis, MO, USA) at various concentrations (20, 40 and 60 ng/ml) over varying time-periods (12, 24 and 36 h) following overnight starvation.
Cell transfection. c-Met small interfering RNA (siRNA) or control siRNA plasmids (Santa Cruz Biotechnology Inc., Dallas, TX, USA) were transfected into PC-3 cells using Lipofectamine ® 2000 transfection reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). Stable transfectants were selected in 10 mg/ml puromycin (Life Technologies, Grand Island, NY USA) 24 h following transfection. Subsequently, the selection medium was replaced every 3 days. Following 2 weeks of selection, resistant clones were isolated. Cells were treated with recombinant human HGF as described above.
MTT assay. The PC-3 cells (5x10 3 /0.2 ml) were plated in 96-well plates and stimulated with HGF (60 ng/ml) for 0, 24, 48 or 72 h. The cultures were incubated with 5 mg/ml MTT (Sigma-Aldrich)for 4 h. The metabolic product was then dissolved in 200 µl buffered dimethyl sulfoxide (Sigma-Aldrich), and the absorbance at 570 nm was measured with a Bio-Rad microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Western blot analysis. Cells were lysed using Extraction and Quantification ProteoJET Mammalian Cell Lysis Reagent (MBI Fermentas, Ontario, Canada) with a protease inhibitors (Roche Diagnostics, Basel, Switzerland). Total protein concentration was estimated using the BCA method (Pierce Biotechnology Inc., Rockford, IL, USA). A total of 30 µg clarified protein lysate was electrophoretically resolved by denaturing 12% SDS-PAGE and electrotransferred onto nitrocellulose membranes (Bio-Rad Laboratories, Inc.). The immunoblots were incubated in 3% bovine serum albumin (Sijiqing Biotech Co. Ltd., Hanzhou, China), 10 mM Tris-hydrochloride (pH 7.5), 1 mM EDTA and 0.1% Tween-20 (Sigma-Aldrich) at room temperature and probed for 1. Ltd., Kaohsiung City, Taiwan). Monoclonal mouse anti-human GAPDH antibody (1:10,000 dilution; Santa Cruz Biotechnology, Inc.) was used as the internal control. Blots were imaged using enhanced chemiluminescence detection system (Pierce Biotechnology, Inc.).
Reverse transcription-polymerase chain reaction (RT-PCR).
Total RNA was isolated from cells using TRIzol reagent (Invitrogen Life Technologies). The isolated RNA was reverse-transcribed into complementary DNA (cDNA) using oligo (dT) primers and Avian Myeloblastosis Virus Reverse Transcriptase (Takara Bio, Inc., Shiga, Japan). cDNA (10 µl) was used as a template for PCR in a final reaction volume of 50 µl. Invitrogen primers were obtained from Thermofisher Scientific, Inc. (Carlsbad, CA, USA): The human C-Met primers (sense, 5'-GTTTCCCAATTTCT-GACC-3' and antisense, 5'-TATATCAAAGGTGTTTAC-3') generated a 516 bp product. The β-actin primers (sense, 5'-TGGGCATGGGTCAGAAGGAT-3' and antisense, 5'-A AG CAT T TG CG GTG GACGAT-3') generated a product of 991 bp. The DNA amplification conditions were as follows: An initial denaturation step at 95˚C for 5 min, 30 cycles at 95˚C for 30 sec, 60˚C for 30 sec, and 72˚C for 40 sec, and a final elongation step at 72˚C for 7 min. The RT-PCR samples were electrophoresed on 1.5% agarose gel and stained with ethidium bromide (0.5 µg/ml); Sigma-Aldrich). Images of the gels were then captured using an ultraviolet transillumination system (Liuyi Biotech Co. Ltd., Beijing, China).
In vitro wound-healing assay. Cells were seeded in 6-well plates and grown to 60-70% confluence. Cells were then incubated in Gibco serum-free medium (Thermofisher Scientifi, Inc.) overnight and treated with HGF (60 ng/ml). Prior to the addition of HGF, 2-mm scratches were made in the confluent cell monolayer with a 200-µl pipette tip. Cell migration into the denuded area was assessed 12 and 24 h following treatment using a Type CK2 optical microscope (Olympus Corporation, Tokyo, Japan).
In vitro Transwell invasion assay. Polycarbonate filters (8 µm; EMD Millipore, Billerica, MA, USA) were coated with 50 µg/cm 2 reconstituted Matrigel (Sigma-Aldrich). Cells (5x10 3 ) were seeded into the upper chamber in 300 µl serum-free growth medium. Cells were incubated under normoxic conditions and allowed to migrate toward the complete growth medium for 24 and 48 h. Non-invading cells were removed mechanically using cotton swabs and cells on the lower surface were subsequently counted microscopically.
Soft agar assay. Cells were resuspended in 2 ml top agar medium (DMEM containing 0.4% low-melting agarose and 10% FBS; Sigma-Aldrich) and then rapidly overlaid on 2 ml bottom agar medium (DMEM containing 0.8% low-melting agarose and 10% FBS) in 6-well culture plates. Following 2-3 weeks of incubation, colonies >0.1 mm in diameter were scored as positive. Colony-formation efficiency was evaluated using a Type CK2 optical microscope (Olympus Corporation).
Statistical analysis. All values are expressed as the mean ± standard deviation of at least three independent experiments. Statistical analysis was performed using Student's t-test. P<0.05 was considered to indicate a statistically significant difference.
Results

HGF induces EMT-like changes in PC-3 cells.
Characteristic changes associated with EMT include downregulation of epithelial markers and upregulation of mesenchymal markers. These changes are associated with the scattered growth of cancer cells, enabling cell-cell dissociation, migration and motility (23) . In the present study, western blot analysis revealed that HGF treatment downregulated E-cadherin expression and upregulated vimentin expression in PC-3 cells in a time-and dose-dependent manner. PC-3 cells acquired stable, EMT-like changes following incubation with HGF (60 ng/ml) for 36 h (Fig. 1A) . These EMT-like changes were not observed at other time-points or HGF concentrations. The changes lasted for 7 days following withdrawal of HGF (Fig. 1B) . These results indicate that HGF promotes reversible changes in the expression of EMT markers in PC-3 cells. Based on these results, PC-3 cells were treated with 60 ng/ml HGF for 36 h in all subsequent experiments. (Fig. 2A) . Furthermore, c-Met was activated by HGF-mediated phosphorylation (p-c-Met) and activated c-Met is able to regulate various downstream target genes. Western blot analysis indicated that HGF treatment increased the expression of c-Met and p-c-Met (Fig. 2B) . Together, these results suggest that HGF upregulates c-Met at the mRNA and protein levels.
c-Met expression is enhanced following HGF treatment.
To investigate the role of HGF in inducing EMT-like changes in PC-3 cells, messenger RNA (mRNA) and protein expression levels of c-Met, the receptor for HGF, were measured. RT-PCR analysis demonstrated an upregulation of c-Met transcription following HGF treatment for 36 h
HGF treatment increases the invasive potential of PC-3 cells.
The effect of HGF treatment on the invasive potential of PC-3 cells was examined. An MTT assay demonstrated that HGF treatment increased cancer cell proliferation and doubling time reduced (Fig. 3A) . In addition, HGF treatment increased the number of tumor colonies that developed in the soft-agar assay (Fig. 3B) . In the wound-healing assay, HGF-treated PC-3 cells demonstrated increased migratory capacity compared with that of the untreated cells (Fig. 3C) . In the Transwell assay, HGF-treated cells displayed increased invasion beneath the insert surface and through the collagen matrix ( Fig. 3D and E) . Taken together, these results demonstrate that HGF increased the invasive potential of PC-3 cells.
ERK/mitogen activated protein kinase (MAPK) signaling is involved in HGF-induced EMT.
To investigate the molecular mechanism underlying HGF-induced EMT, the changes in ERK/MAPK expression levels following HGF incubation were measured. Western blot analysis indicated that HGF treatment increased the expression levels of ERK and p-ERK. In addition, HGF treatment increased the expression of Zeb-1, a direct suppressor of E-cadherin. Thus, the ERK/MAPK signaling pathway was involved in HGF-induced EMT (Fig. 4) . treated with control siRNA, however, this was not observed in cells treated with c-Met siRNA (Fig. 5C) . Together, these data suggest that HGF induces EMT-like changes in a c-Met-dependent manner.
Discussion
HGF binds to its receptor, c-Met, and activates it through auto-phosphorylation, which induces the transcription of downstream target genes. Under normal physiological conditions, the HGF/c-Met signaling pathway regulates tissue and organ regeneration. Furthermore, HGF is significant in the modulation of cell morphology, and induction of angiogenesis and lymphangiogenesis (24) .
Previous studies have indicated that HGF stimulates proliferation, migration and invasion in numerous types of cancer, including colon, stomach, lung, bladder and prostate cancer (17) . For example, HGF levels are elevated in the serum of patients with prostate cancer. Furthermore, elevated HGF levels are associated with metastatic disease independent of prostate-specific antigen levels or age, and are associated with a decrease in overall survival rate (25, 26) . In addition, Duhon et al (27) reported that HGF treatment of DU145 prostate tumor cells stimulated the phosphoinositide 3-kinase (PI3K) and MAPK signaling pathways, leading to increased cell scattering, motility and invasion. These effects were prevented by treatment with epigallocatechin-3-gallate.
Although HGF accelerates the progression of prostate cancer, the underlying mechanisms remain to be elucidated. The association between HGF and EMT has been demonstrated in various cancer models (28, 29) . However to the best of our knowledge, no such association has previously been reported in prostate cancer. One study demonstrated that HGF induced EMT in DU145 cells (30) ; however, DU145 cells are EMT-positive (18, 31, 32) . Therefore, the present study investigated the effect of HGF on EMT induction in PC-3 cells.
Typical characteristics of EMT include downregulation of epithelial markers, for example E-cadherin, and upregulation of mesenchymal markers, including vimentin, N-cadherin and α-smooth muscle actin (33, 34) . In particular, downregulation of E-cadherin is a key step in the induction of EMT (35) . Intercellular adhesions are critical for maintaining the epithelial phenotype, and since E-cadherin is essential for adherent junctions, downregulation results in the loss of cell polarity and abnormal differentiation, thus facilitating EMT (9, 36) .
In the present study, treatment of PC-3 cells with HGF resulted in EMT-like changes, as indicated by the downregulation of E-cadherin and upregulation of vimentin. Thus, HGF induced an EMT-like phenotype in PC-3 cells in a time-and concentration-dependent manner. Further studies indicated that HGF stimulation increased the proliferation, migration, invasion and tumorigenicity of cancer cells. The EMT-like changes were reversible following withdrawal of HGF for 7 days, which was similar to the EMT phenotype induced by TGF-β1 (37) . These results suggested that growth factors are required to maintain the EMT phenotype. Numerous growth factors, including FGF, IGF, TGF-β and HGF, are secreted from stromal cells (38) . Under continued stimulation from these growth factors, cancer cells acquire a stable EMT phenotype. Therefore, the results of the present study demonstrate the bidirectional interaction and co-evolution of tumors and their stroma in cancer progression.
The effect of HGF on the expression of its receptor c-Met, at the mRNA and protein levels, was investigated. c-Met overexpression has been identified in the majority of human cancers (39, 40) . In the present study, c-Met expression was promoted by HGF-dependent transcriptional upregulation. This result is consistent with the findings of Boccaccio and Comoglio (41) regarding prostate cancer. Notably, in the present study, there was a marked elevation in p-c-Met following HGF treatment, demonstrating that HGF activates c-Met in prostate cancer cells. Knockdown of c-Met by siRNA prevented HGF-induced EMT-like changes. These results demonstrate that HGF induced EMT in a c-Met-dependent manner in PC-3 cells.
Various oncogenic effects of HGF and c-Met are mediated by a complex downstream signaling network, most prominently the MAPK and PI3K/Akt signaling pathways (42) . In the present study, ERK was phosphorylated by HGF, and PC-3 cells expressed high basal levels of p-ERK and ERK. These changes were blocked by c-Met knockdown using siRNA. These data suggested that the functional expression of ERK is significant in HGF-induced EMT in PC-3 cells. A comparable effect was observed in HGF-induced EMT in hepatocellular cancer (43) .
The present study demonstrated that HGF upregulated Zeb-1 in PC-3 cells. As with other zinc finger transcription factors, including SNAIL and SLUG, Zeb-1 has been linked to E-cadherin repression (44) . Repression of E-cadherin enhances the ability of cancer cells to migrate to distant sites (45) . HGF interacts with early growth response factor-1 through the MAPK signaling pathway, which binds to the Snail promoter, leading to rapid induction and execution of EMT (46) . Another study revealed that the Zeb gene was activated upon activation of SNAIL (47) . SW480 colorectal cancer cells possess a mesenchyme-like phenotype, which is characterized by loosely attached cells that lack membranous E-cadherin. Silencing of Zeb-1 by siRNA resulted in a cellular phenotype resembling the mesenchymal-epithelial transition (48) . The results of the present study are consistent with the above-mentioned studies, and demonstrate the role of Zeb-1 in EMT in prostate cancer.
In conclusion, the results of the present study revealed that HGF directly promotes EMT and carcinogenic properties in prostate cancer via the ERK signaling pathway. Specific molecular targeting of this signaling pathway may provide therapeutic benefit in patients exhibiting prostate cancer.
